LGND

Ligand Pharmaceuticals Incorporated Press Releases

$48.74
*  
2.05
4.04%
Get LGND Alerts
*Delayed - data as of Sep. 19, 2014  -  Find a broker to begin trading LGND now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Ligand Licenses Captisol-enabled™ Lamotrigine to CURx Pharmaceuticals, Inc.
9/9/2014 8:30:00 AM - Business Wire

Lemelson Capital Management Marks Flagship Fund's Second Anniversary
9/5/2014 9:03:00 AM - PR Newswire

Ligand Partner GlaxoSmithKline Receives U.S. FDA Approval for Promacta®/Revolade™ For Use in Patients with Severe Aplastic Anemia
8/27/2014 8:00:00 AM - Business Wire

Lemelson Capital Comments on Large Institutional Selling in Shares of Ligand Pharmaceuticals Amidst Company's Insolvency and Mounting Going Concern Risk
8/25/2014 11:43:00 AM - PR Newswire

Avion Pharmaceuticals, LLC, signs Captisol® License Agreement with Ligand Pharmaceuticals to develop four new products
8/15/2014 9:30:00 AM - PR Newswire

Lemelson Capital Says Ligand Pharmaceuticals' $225M Debt Issuance Solidifies Company's Insolvency, Substantially Raises Specter of Bankruptcy
8/14/2014 9:15:00 AM - PR Newswire

Ligand Signs Multi-Program Captisol® License Agreement with Avion Pharmaceuticals
8/14/2014 8:00:00 AM - Business Wire

Ligand Prices Offering of $225 Million of Convertible Senior Notes
8/13/2014 8:00:00 AM - Business Wire

Ligand Announces Proposed Offering of $225 Million of Convertible Senior Notes and Announces $200 Million Share Repurchase Program
8/11/2014 4:01:00 PM - Business Wire

Lemelson Capital Management Further Increases Short Position in Ligand Pharmaceuticals (NASDAQ: LGND), Updates LGND Research Report with New Material Information
8/4/2014 2:46:00 PM - PR Newswire

Ligand Reports Second Quarter 2014 Financial Results
8/4/2014 8:30:00 AM - Business Wire

Ligand Partner GSK Announces Record Quarterly Promacta™/Revolade™ Revenue of $92 Million
7/23/2014 9:30:00 AM - Business Wire

Ligand Partner SAGE Therapeutics Receives Fast Track Designation for Captisol-enabled SAGE-547 to Treat Status Epilepticus
7/22/2014 1:15:00 PM - Business Wire

Lemelson Capital Management Announces TTM and Second Quarter 2014 Performance Results for The Amvona Fund
7/17/2014 11:53:00 AM - PR Newswire

Ligand Reports Second Quarter Revenues and Announces Share Repurchase Program
7/17/2014 8:00:00 AM - Business Wire

Ligand Chairman Dr. John W. Kozarich Named Director of the Year Honoree by Corporate Directors Forum
7/14/2014 8:30:00 AM - Business Wire

Lemelson Capital Management Further Increases Short Position in Ligand Pharmaceuticals (NASDAQ: LGND), Appends its LGND Research Report
7/7/2014 9:00:00 AM - PR Newswire

Ligand Partner GSK Announces the Start of a Phase 3 Study with Eltrombopag in Patients with Myelodysplastic Syndromes
6/25/2014 8:30:00 AM - Business Wire